Loading NYT detail
Loading ticker data...
Loading NYT detail
The New York Times Company, together with its subsidiaries, provides news and information for readers and viewers across various platforms worldwide.
It offers The New York Times (The Times), a daily and Sunday newspaper in the United States, as well as international edition of The Times; and operates the NYTimes. com Website. The company also transmits articles, graphics, and photographs from The Times and other publications to approximately 1,500 newspapers, magazines, and websites; licenses electronic databases to resellers in the business, professional, and library markets; and offers magazine licensing, news digests, book development, and rights and permissions. In addition, it engages in the live events business, which hosts physical and virtual live events to connect audiences with journalists and outside thought leaders; direct-sold website, mobile application, podcast, email, and video advertisements, as well as digital advertising services; operates Wirecutter, a product review and recommendation products; develops mobile applications, including games and cooking products; prints and distributes products for third parties; and offers other products and services. The company was founded in 1851 and is headquartered in New York, New York.
Chart data unavailable
The New York Times stock price has been in a strong bull run and is hovering near its all-time high despite President Donald Trump claiming that it is “failing”. NYT was trading at $82.50 on Thursday, down slightly from its all-time high of $87.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ChowChow To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in ChowChow between September 16, 2025 and December 10, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - April 9, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against ChowChow Cloud International Holdings Limited ("ChowChow" or the "Company") (NYSE American: CHOW) and reminds investors of the May 12, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Picard Medical To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Picard Medical between September 2, 2025 and October 31, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - April 9, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Picard Medical, Inc. ("Picard Medical" or the "Company") (NYSE American: PMI) and reminds investors of the April 13, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Concorde To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Concorde between April 21, 2025 and July 14, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - April 9, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Concorde International Group, Ltd.
Senior leadership roles at Guardant Health, Genentech and Pfizer Regulatory, clinical and commercial expertise in therapeutics and biomarkers Will assist with osteosarcoma regulatory advice and oncology pipeline prioritization New York, New York--(Newsfile Corp. - April 8, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, listeria-based cancer immunotherapies, today announced that Craig Eagle, MD, was appointed to the Company's newly-formed strategic advisory board. The Company's strategic advisory board is being formed to assist the Company in fine-tuning its osteosarcoma regulatory execution plan and to help develop a detailed pipeline development plan to prioritize the highest value opportunities beyond osteosarcoma.
New York, New York--(Newsfile Corp. - April 8, 2026) - GridStor, a developer and operator of utility-scale battery energy storage systems, and Axpo, a leading international energy company headquartered in Switzerland, announced today the execution of an Energy Storage Agreement with the Hidden Lakes Reliability Project, a 220 MW, 440 MWh battery energy storage system located in Galveston County, Texas, which began operations in 4Q2025. In brief: GridStor and Axpo have executed an Energy Storage Agreement for the Hidden Lakes Reliability Project, a 220 MW, 440 MWh battery storage system in Galveston County, Texas.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Concorde To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Concorde between April 21, 2025 and July 14, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - April 7, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Concorde International Group, Ltd.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Picard Medical To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Picard Medical between September 2, 2025 and October 31, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - April 7, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Picard Medical, Inc. ("Picard Medical" or the "Company") (NYSE American: PMI) and reminds investors of the April 13, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ChowChow To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in ChowChow between September 16, 2025 and December 10, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - April 7, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against ChowChow Cloud International Holdings Limited ("ChowChow" or the "Company") (NYSE American: CHOW) and reminds investors of the May 12, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Concorde To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Concorde between April 21, 2025 and July 14, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - April 5, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Concorde International Group, Ltd.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ChowChow To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in ChowChow between September 16, 2025 and December 10, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - April 5, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against ChowChow Cloud International Holdings Limited ("ChowChow" or the "Company") (NYSE American: CHOW) and reminds investors of the May 12, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Picard Medical To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Picard Medical between September 2, 2025 and October 31, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - April 5, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Picard Medical, Inc. ("Picard Medical" or the "Company") (NYSE American: PMI) and reminds investors of the April 13, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
SG Americas Securities LLC trimmed its holdings in shares of The New York Times Company (NYSE: NYT) by 24.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 43,940 shares of the company's stock after selling 14,087
Elon Musk is requiring banks and other advisers working on SpaceX's planned IPO to buy subscriptions to Grok, his artificial intelligence chatbot, the New York Times reported on Friday, citing people familiar with the matter.
Company expects approximately $2 million in non-dilutive VAT refunds from wholly owned U.K. subsidiary in 2Q-26 Company expects to receive approximately $2 million in non-dilutive R&D tax credits repayable to the company in cash from its U.K. subsidiary in 2H-26 Offering net proceeds, together with funds expected to be received via U.K. subsidiary, expected to provide cash runway into 2027 Company expects to receive approvals in the U.S., U.K. and Europe for OST-HER2 in the prevention of delay of recurrent, fully resected, pulmonary metastatic osteosarcoma in the second half of 2026 New York, New York--(Newsfile Corp. - April 2, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, listeria-based cancer immunotherapies, today announced it that it has completed a $5.25 million registered direct offering of common stock (or pre-funded warrants in lieu thereof) and warrants, with participation primarily from high-net-worth investors who have invested in several of the Company's prior financing rounds. Each investor was issued either shares of common stock at a purchase price of $1.40 per share or, in lieu thereof, pre-funded warrants at a purchase price of $1.399 per pre-funded warrant, together with one warrant to purchase one share of common stock at an exercise price of $1.40 per share for each share of common stock issued or issuable upon exercise of the pre-funded warrants.
